Werewolf Current Deferred Revenue from 2010 to 2026
| HOWL Stock | USD 0.61 0.03 4.69% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 816.3 K | Current Value 775.5 K | Quarterly Volatility 2.5 M |
Check Werewolf Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Werewolf Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.5 M, Depreciation And Amortization of 1.1 M or Interest Expense of 5.6 M, as well as many indicators such as Price To Sales Ratio of 32.15, Dividend Yield of 0.0 or PTB Ratio of 0.95. Werewolf financial statements analysis is a perfect complement when working with Werewolf Therapeutics Valuation or Volatility modules.
Werewolf | Current Deferred Revenue | Build AI portfolio with Werewolf Stock |
Historical Current Deferred Revenue data for Werewolf Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Werewolf Therapeutics represents a compelling investment opportunity.
Latest Werewolf Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Werewolf Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Werewolf Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Werewolf Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Werewolf Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 5,195,399 | |
| Geometric Mean | 4,042,055 | |
| Coefficient Of Variation | 47.81 | |
| Mean Deviation | 2,044,213 | |
| Median | 6,532,000 | |
| Standard Deviation | 2,483,916 | |
| Sample Variance | 6.2T | |
| Range | 5.8M | |
| R-Value | (0.74) | |
| Mean Square Error | 3T | |
| R-Squared | 0.54 | |
| Significance | 0.0007 | |
| Slope | (362,591) | |
| Total Sum of Squares | 98.7T |
Werewolf Current Deferred Revenue History
About Werewolf Therapeutics Financial Statements
Werewolf Therapeutics investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Werewolf Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 816.3 K | 775.5 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Werewolf Therapeutics Correlation against competitors. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.